NOVOSIBIRSK, December 12Scientists from the Research Institute of Clinical and Experimental Lymphology (NIIKEL, a branch of the Institute of Cytology and Genetics SB RAS) have developed an antibacterial gel for the rapid healing of wounds, including gunshot and shrapnel wounds, the scientific institute reported on Tuesday.
The Institute of Cytology and Genetics SB RAS explained: from 0.3 to 1.6% of elderly people in Russia suffer from non-healing skin lesions – trophic ulcers. 19% of patients with diabetes have such problems, and the number of such patients is steadily growing. Treatment is often complicated by bacterial resistance to antibiotics. Thus, there is an urgent need to create a new safe antibacterial and antifungal agent.
«
“Researchers have developed a prototype drug based on an antibacterial peptidomimetic and an inert polymer gel for the treatment of infectious lesions of the skin and subcutaneous tissue. The product effectively destroys pathogenic bacteria and promotes faster wound healing,” said Pavel Madonov, head of the experimental pharmacology department at NIIKEL.
< /span>
He explained that scientists introduced the synthetic antimicrobial peptidomimetic KAMP-1 into the gel. This is an antibacterial component to which it is difficult for microorganisms to develop resistance.
“The principle of action of an antibacterial peptidomimetic is that it adheres to the membrane of the bacterium and leads to its death. The antimicrobial peptidomimetic is effective against various pathogens, including fungi of the genus Candida,” noted He.
Studies have shown that a gel with a peptidomimetic provides antibacterial sanitation on the surface of the wound and in the adjacent layers of the dermis without significant absorption into the systemic bloodstream. Thus, the drug does not exhibit high toxicity. Such an antimicrobial gel can be in demand in surgery and in the treatment of infectious skin lesions. The drug being developed will be effective for patients with trophic ulcers, long-term non-healing wounds, as well as gunshot and shrapnel wounds, the scientific institute noted.
“The antimicrobial activity of the peptidomimetic KAMP-1 has now been tested. In the coming years, it is planned to begin first preclinical tests on animals, and then clinical studies. The launch of the new drug into production, according to preliminary forecasts, is possible in 2030,” – added to the Institute of Cytology and Genetics SB RAS.
Recent Comments